20
Views
112
CrossRef citations to date
0
Altmetric
DNA Dynamics and Chromosome Structure

Xeroderma Pigmentosum Group A Protein Loads as a Separate Factor onto DNA Lesions

, , , , , , , & show all
Pages 5755-5767 | Received 28 Mar 2003, Accepted 23 May 2003, Published online: 27 Mar 2023
 

Abstract

Nucleotide excision repair (NER) is the main DNA repair pathway in mammals for removal of UV-induced lesions. NER involves the concerted action of more than 25 polypeptides in a coordinated fashion. The xeroderma pigmentosum group A protein (XPA) has been suggested to function as a central organizer and damage verifier in NER. How XPA reaches DNA lesions and how the protein is distributed in time and space in living cells are unknown. Here we studied XPA in vivo by using a cell line stably expressing physiological levels of functional XPA fused to green fluorescent protein and by applying quantitative fluorescence microscopy. The majority of XPA moves rapidly through the nucleoplasm with a diffusion rate different from those of other NER factors tested, arguing against a preassembled XPA-containing NER complex. DNA damage induced a transient (∼5-min) immobilization of maximally 30% of XPA. Immobilization depends on XPC, indicating that XPA is not the initial lesion recognition protein in vivo. Moreover, loading of replication protein A on NER lesions was not dependent on XPA. Thus, XPA participates in NER by incorporation of free diffusing molecules in XPC-dependent NER-DNA complexes. This study supports a model for a rapid consecutive assembly of free NER factors, and a relatively slow simultaneous disassembly, after repair.

ACKNOWLEDGMENTS

We thank Leon Mullenders and Roel van Driel for support and stimulating discussion and K. Tanaka (Osaka, Japan) and O. Nikaido (Kanazawa, Japan) for kindly providing polyclonal XPA antisera and anti-CPD monoclonal antibodies, respectively.

This work was supported by grant NWO-ALW 805-33-441-P and investment grants NWO GB-MW 903-68-370 and 901-01-229 from The Netherlands Organization for Scientific Research, by The Dutch Cancer Society (KWF) EUR 1999-2004, and by the Louis Jeantet Foundation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.